Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
GT Biopharma Logo
GT Biopharma Growth Score
56
CB Rank
38663
Heat Score
71
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Westlake Village, California, United States1-10 www.gtbiopharma.com/
Biotechnology
Health Care
Medical
Overview

GT Biopharma
Total Funding
obfuscation
Growth Score
56
Heat Score
71

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score56
-18 pts
in past quarter
Heat Score 71
5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About GT Biopharma

CB Rank
38663
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Westlake Village, California, United States1-10 www.gtbiopharma.com/
Biotechnology
Health Care
Medical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name GT Biopharma, Inc.
Also Known As Oxis International
Operating Status Active
Stock Symbol  EPA:GTBP
Company Type For Profit
Founders  Kathleen E. Clarence-Smith, STEVEN WELDON
About the Company

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural Killer (NK) cell engager platform. The TriKE™ NK protein biologic platform is designed to harness and amplify the

body’s native immune system for hope for patients with cancer and infectious diseases.

Phone Number 310-860-5184
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
GT Biopharma is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

TriKE® Therapeutic Agents
TriKE® agents are immunotherapeutic molecules that engage natural killer (NK) cells and cancer cells to promote selective killing of cancer cells.
GTB-3550 TriKE®
GTB-3550 is a first-generation TriKE® molecule targeting CD16 on NK cells and CD33 on tumor cells, with an IL-15 component to activate NK cells, developed for AML and MDS treatment.

Research & Development

GT Biopharma is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of Armando Soto
Armando Soto
No
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
Photo of Armando Soto
Armando Soto
No
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
Photo of Armando Soto
Armando Soto
No
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
Photo of Armando Soto
Armando Soto
No
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—
Photo of Armando Soto
Armando Soto
No
Post-IPO Equity - GT Biopharma Logo
Post-IPO Equity - GT Biopharma
—

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 6 Board Members and Advisors 1 Contacts 4

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,041
-32.58%
 in past month

IT Spend

$32.6KThis year, GT Biopharma is projected to spend $32.6K on IT, according to Aberdeen.

Actively Used Products

9GT Biopharma uses 9 technology products and services including HTML5, Google Analytics, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

3GT Biopharma is actively using 3 technologies for its website, according to BuiltWith. These include CommonCrawl Top 5m, CommonCrawl Top 10m, and  Vimeo.

Total IP

11The intellectual property of GT Biopharma includes 9 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, GT Biopharma has registered 2 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is GT Biopharma's headquarters? GT Biopharma is located in Westlake Village, California, United States.Who invested in GT Biopharma? GT Biopharma is funded by Armando Soto.When was the last funding round for GT Biopharma? GT Biopharma closed its last funding round on
obfuscation
from a Post-IPO Equity round.How much funding has GT Biopharma raised to date? GT Biopharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(b4ae374 1)
|